Unexpected increase of Hepatitis B Surface Antigen (HBsAg) levels during treatment with nucleos(t)ide analogous 12–24 months before virological breakthrough and resistance
S Wiegand, J Jaroszewicz, B Zacher, K Wursthorn, K Deterding, MP Manns, H Wedemeyer, M Cornberg · Zeitschrift für Gastroenterologie · 2012 · Heft 01
Bibliografische Angaben
Zusammenfassung
Introduction: HBsAg levels differ in the course of chronic hepatitis B virus infection and may predict the response to treatment with interferon alpha. Recently, we have shown that significant HBsAg decline during treatment with nucleos(t)ide analogues (NA) is associated with later HBsAg loss (Jaroszewicz et al., AVT 2011; GASL 2011). So far there is little data if resistance to NA affects HBsAg levels. Methods: In this retrospective study, HBsAg was quantified longitudinally in 30 patients with virological breakthrough (VB) due to NA resistance (VB-R: 27 LAM, 3 ADV). We have selected a control group of 30 patie…
